Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Molecular Mechanism of Nasopharyngeal Carcinoma

9 september 2005 uppdaterad av: National Taiwan University Hospital

the Garduate Institute of Microbiology in National Taiwan University

EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses. Unlike other human herpes viruses, EBV can only predominately infect two types of human cells: lymphoid cells and epithelial cells and its infection is associated with several human malignancies of these two cell types. The lymphoid cancers associated with EBV infection include Burkitt's lymphoma, Hodgkin's disease, B lymphoma in immunodeficient patients and T/NK cell lymphoma. The carcinomas associated with EBV are nasopharyngeal carcinoma and gastric carcinoma. One unique biological feature of EBV is that it can infect and immortalize primary B lymphocytes in vitro into lymphoblastoid cell lines (LCL). So far, limited information is known about the whole EBV infection process and its regulation mechanism for immortalization. In this project, three EBV infection models are setting up to reveal the cellular events and signal transduction pathway possibly involved in EBV infection process and immortalization course of action.

Studieöversikt

Status

Okänd

Detaljerad beskrivning

Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC individuals are usually ten years younger than those of patients with other head and neck cancers. Clinically, this early onset and high incidence of metastasis in NPC may contribute to its poor prognosis. Fortunately, NPC is usually radio-and chemo-therapy sensitive during the early stage. So, the more we understand NPC pathogenesis, the more efficient detection methods would be developed for NPC early diagnosis and prognosis.

Four unique characteristics have been reported for NPC: geographic preference, heavy infiltration of lymphocytes, high incidence of metastasis and association with Epstein-Barr virus (EBV). According to our hypothesis that both cellular changes and viral factors are crucial for NPC development, four major long-term study goals have been carried out in our lab: (1) identification and characterization of the cellular and viral factors that are involved in NPC formation, (2) elucidation of potencies of these molecules as clinical diagnosis and prognosis markers of NPC, (3) investigation of the molecular and biological linkage between EBV infection and NPC development and (4) establishment of a drug-screening system for NPC chemotherapy.

Based on our assumption that both cellular genes and viral factors are involved in NPC carcinogenesis, the following genes are chosen as the major study targets in this five-year grant. Firstly, to asses the alteration of cellular gene expression, we choose three cytokine genes 【interleukin (IL)-1, IL-7 and IL-13】, three inhibitors of apoptosis proteins (IAP) genes (survivin, HIAP-1, and HIAP-2), two specific cellular genes (osteoblast-specific factor-2 and polymeric immunoglobulin receptor) and one tumor suppressor gene (tumor susceptibility gene TSG101) in our proposal. All these genes exhibit special expression profiles in NPC biopsies in our preliminary study. So, the regulation and effect of these genes in epithelial cells would be the study focus. Secondly, two EBV viral genes, Zta and LMP2A, the former encoded immediately early lytic product and the later encoded latent membrane protein, are selected for this study. In our previous grant, we found that Zta can up-regulate TKT (trk-related tyrosine kinase) and matrix metalloproteinases (MMP)-1 which is a down-stream effector of TKT. Therefore we will extend the study on how Zta and LMP2A regulate and influence anti-apoptotic network and metastasis progression. Based on our preliminary data, this proposal is highly approachable and the results may provide valuable information for NPC diagnosis, prognosis and treatment.

Studietyp

Observationell

Inskrivning

25

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Taipei, Taiwan, 100
        • Rekrytering
        • National Taiwan University College of Medicine
        • Kontakt:
        • Huvudutredare:
          • Ching-Hwa Tsai, pH.D

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

30 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • diagnosis of nasopharyngeal carcinoma

Exclusion Criteria:

-

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Ching-Hwa Tsai, Ph D, National Taiwan University College of Medicine

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 januari 2005

Avslutad studie

1 augusti 2005

Studieregistreringsdatum

Först inskickad

9 september 2005

Först inskickad som uppfyllde QC-kriterierna

9 september 2005

Första postat (Uppskatta)

12 september 2005

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

12 september 2005

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 september 2005

Senast verifierad

1 januari 2005

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Nasofaryngealt karcinom

3
Prenumerera